Is it time to replace BASDAI with ASDAS?
Por um escritor misterioso
Descrição
Measures of symptoms and disease status in ankylosing spondylitis
Achievement of Remission Endpoints with Secukinumab Over 3 Years
Low BASDAI score alone is not a good predictor of anti-tumor
Construct validity and responsiveness of the simplified version of
Comparison of disease activity in patients with ankylosing
The predictability of ASDAS on drug survival in patients with
The Ankylosing Spondylitis Disease Activity Score Reflects and
ASAS 20/40 response rates, and mean change from baseline in BASDAI
The Sensitivity to Change of the ASAS Health Index in an
Change from baseline in ASDAS-CRP, CRP and BASDAI over time to
de
por adulto (o preço varia de acordo com o tamanho do grupo)
